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Myocardial dysfunction frequently accompanies severe sepsis and septic shock.
Although previously described as a preterminal event, ventricular dysfunction with
reduced ejection fraction and biventricular dilatation is present in most patients with
severe sepsis and septic shock. In survivors, this depression in cardiac function is
reversible over the course of seven to ten days. Even though some prognostic factors
have been identified in patients with sepsis-induced myocardial dysfunction, their
measurement often includes costly and cumbersome techniques. Thus, there is a
need for an inexpensive, simple, rapid and readily available marker to predict
mortality in septic shock. At present, a relationship between BNP with myocardial
dysfunction in septic shock has not been evaluated. However, growing evidence
supports the hypothesis that BNP could be an early predictor of mortality in septic
shock. If proven, the hypothesis would have important clinical and public health
implications.
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Brain natriuretic peptide (BNP), a cardiac neuro-
hormone, is the second member of a family of
polypeptides secreted by the cardiac ventricles inernational Society for Infectious Diseases.
272 J.R. Castillo et al.response to volume expansion and pressure over-
load.1 Physiologically, BNP promotes natriuresis and
diuresis, as well as vasodilatory actions via antag-
onism of the renin-angiotensin-aldosterone sys-
tem.1,2
As a diagnostic test, BNP is an accurate marker
for left ventricular dysfunction from different
causes such as ischemic and non-ischemic dilated
cardiomyopathies.3 Elevated plasma levels of BNP
are associated with multiple echocardiographic
parameters of systolic and diastolic dysfunction.3,4
Previous studies in symptomatic and asymptomatic
patients found that a BNP level of 18 pg/mL or more
had a sensitivity of 92% and a specificity of 72% for a
diminished left ventricular ejection fraction (LVEF)
of 30% or less.5
Sepsis and septic shock represent an increasingly
important clinical problem. It has been recently
estimated that severe sepsis causes more than
200,000 deaths per year, the majority of which
are due to cardiovascular collapse.6 As a systemic
inflammatory response to infection, sepsis induces
the endogenous release of a wide spectrum of
mediators with deleterious cardiovascular effects.
When this response is severe, alterations in cardio-
vascular homeostasis lead to septic shock. One of
the most important manifestations of septic shock is
myocardial dysfunction.7
The early assessment of myocardial depression
and its severity, as well as the prediction of mor-
tality in patients with septic shock, usually involves
cumbersome techniques that require special equip-
ment and expertise. Thus, readily measurable cir-
culating biomarkers could facilitate the diagnosis
and possibly even the prevention of cardiovascular
collapse in these patients.Myocardial depression in septic shock
Myocardial depression is well recognized as an early
feature of human septic shock, causing absence of
appropriate oxygen supply to peripheral tissues and
subsequent death. Early systolic dysfunction has
been identified in these patients and seems to be
inversely related to mortality.8,9 Prior work with
radionuclide cineangiography demonstrated that in
survivors of septic shock, the left ventricular cavity
acutely increases in size, as evidenced by an
increase in the left ventricular end-diastolic volume
index (LVEDVI), and the LVEF decreases transiently,
returning to normal in seven to ten days.10 In con-
trast, patients with septic shock who die maintain a
normal LVEF and LVEDVI throughout the course of
their illness. Studies in septic and non-septic criti-
cally ill patients showed a decreased left ventricularstroke work index (LVSWI) in response to equivalent
increments in the LVEDVI.11 Similarly, right ventri-
cular systolic dysfunction with transient dilatation
and a decrease in right ventricular ejection fraction
has also been described.12,13
As regards diastolic function in sepsis, previous
reports have shown a concordance between the
pulmonary artery wedge pressure and the left ven-
tricular end-diastolic volume. Some studies using
echocardiography, however, have demonstrated
slower left ventricular filling and abnormal relaxa-
tion in septic patients, suggesting that impaired
compliance may also play a role.14—16
Various invasive studies with hemodynamic mea-
surements have reported that the inability to
acutely dilate the left ventricle and to decrease
the LVEF along with a persistently low LVEDVI may
be markers for increased mortality.7,9 In addition, a
persistently low cardiac index (CI) and systemic
vascular resistance, as well as a progressive
increase in the heart rate, have been related to
subsequent death.9,11 Similarly, right ventricular
dysfunction has also been associated with a poor
outcome but the data supporting this association
are less convincing.12,13,17,18 Thus, both echocar-
diographic and invasive hemodynamic parameters
of systolic and diastolic dysfunction may be helpful
in predicting outcomes in sepsis. Nonetheless,
acquisition of these data may be expensive, time-
consuming and not always technically reliable.Natriuretic cardiac neurohormones in
sepsis and septic shock
The role of neurohormonal markers of myocardial
dysfunction in sepsis has been reported in both
animal and human models. Hartemink et al.19 found
that right and left systolic dysfunction correlated
with an increase in plasma levels of a-atrial
natriuretic peptide (a-ANP) and its second messen-
ger cyclic guanosine monophosphate (cGMP) during
the first 72 hours after the diagnosis of septic shock.
In measurements of hemodynamic variables with a
pulmonary artery catheter, both the right ventricle
stroke work index and the LVSWI correlated inver-
sely with the serum levels of a-ANP and cGMP. The
optimum cutoff values of these markers for a pre-
diction of a LVSWI <35 g/m2 were 172 pg/mL and
4.5 mg/mL respectively, with a sensitivity and spe-
cificity of 68% and 82%, respectively for aANP and
77% and 93%, respectively for cGMP. Further, levels
of ANP and cGMP were also found to be significantly
lower in survivors than in non-survivors.
The precursor of a-ANP, pro-ANP, has been stu-
died as a novel hormone marker of cardiac depres-
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a potential predictor of acute respiratory distress
syndrome (ARDS).20 Atrial plasma concentrations of
pro-ANP were measured in 17 septic patients, show-
ing a negative correlation with CI. Further, higher
values resulted in patients who developed ARDS. C-
type natriuretic peptide (CNP) has also been asso-
ciated with sepsis. Septic patients had a markedly
elevated serum level of CNP (13.2  10 fmol/mL;
normal 1.4  0.6 fmol/mL) when compared to
patients with congestive heart failure and hyper-
tension.21
Currently there is only one retrospective study
that has evaluated BNP production in the peripheral
circulation in relation to cardiovascular function
and systemic inflammation.22 In a group of 17
patients with septic shock and 19 controls in the
intensive care unit (ICU), elevated blood levels of a-
ANP (82.7  9.9 vs. 14.9  1.2 pg/mL) and BNP
(12.4  3.6 vs. 5.5  0.7 pg/mL) were demon-
strated. a-ANP was found to correlate directly with
levels of IL-6 (r = 0.73, p < 0.01) and BNP to
correlate inversely with the CI (r = 0.56, p <
0.05). BNP showed the highest levels in patients
with septic shock on day 0 (12.4  3.6 pg/mL)
without significant differences up to day four (9.8
 2.1 pg/mL). As has been previously reported in
other studies, a decrease in the LVSWI was observed
in these patients, suggesting a diminished LVEF. A
compensatory increased filling volume of the left
ventricle, along with the consequent rise in the
ventricular distension and the plasma levels of
BNP were also proposed. No relationship with mor-
tality was found.
In a recently presented study (Abstract presented
at the AHA Annual Meeting, 10 November 2003,
Orlando, FL) 13 critically ill and mechanically ven-
tilated patients with septic shock, as well as 18 age-
matched controls, had levels of BNP followed during
their ICU stay. Comparison of ICU admission BNP
plasma levels between patients (849.4  154.8 pg/
mL) and healthy individuals (100  9.4 pg/mL)
showed that plasma levels of BNP in patients with
septic shock were significantly higher (p < 0.05).
For patients who recovered from septic shock
(n = 9), plasma BNP levels after recovery (351.7
 136.6 pg/mL) were significantly lower than on
admission to the ICU, but remained significantly
higher than BNP levels in healthy subject levels
(p < 0.05). Mortality was not evaluated.
BNP is a relatively inexpensive and simple test,
which is now widely available in clinical practice.
BNP is also a predictor of both echocardiographic
parameters of ventricular dysfunction as well as
clinical outcomes in patients with acute and chronic
heart disease. BNP has also been hypothesized to bea marker for ventricular dysfunction in patients with
the human immunodeficiency virus.23,24 The rela-
tionship of BNP with myocardial dysfunction and
mortality in septic shock has not yet been evaluated
in a prospective study.Hypothesis
The hypothesis here assumes that BNP is a marker
for mortality in septic shock-associated myocardial
dysfunction. It is believed that ventricular dilata-
tion and decreases in both the LVEF and the RVEF in
the initial phase of myocardial depression during
septic shock will cause plasma levels of BNP to rise.
Among patients with septic shock who will survive,
BNP will return to normal within the first ten days.
Among patients with septic shock destined to die,
however, BNP will remain within normal limits
because their cardiac ventricles will not increase
in size and their ejection fraction remains normal.Testing the hypothesis
To test this hypothesis, an initial observational
study is needed in patients with septic shock in
whom echocardiographic and hemodynamic para-
meters (mainly LVEDVI, LVSWI and CI) were mea-
sured in the initial phases and throughout the course
of their illness. Plasma levels of BNP will be mea-
sured at the time of diagnosis and sequentially
during the course of the septic shock. The inter-
relationship of BNP, ventricular dilatation, and mor-
tality will also be evaluated. Furthermore it may be
informative to evaluate BNP, echocardiographic
and hemodynamic parameters in non-septic criti-
cally ill patients.
At the present time, the hypothesis that BNP is
a marker of mortality in septic shock is plausible.
If, in the future, a body of evidence emerges to
support this hypothesis, utilization of BNP as a
marker for mortality in septic shock would have
major clinical and public health implications.
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